Universal flu vaccine BiondVax goes robustly beyond first phase II trial

The prospects of a "universal" flu vaccine becoming a pharmaceutical reality have received a boost with positive results from the first Phase II trial of an investigational product from the Israeli biotech company BiondVax Pharmaceuticals.

More from Anti-infective

More from Therapy Areas